🇺🇸 FDA
Company

ProQR

ProQR Therapeutics N.V.

PRQR pharma USA

Quick answer

ProQR is a pharma company (PRQR) headquartered in LEIDEN, USA with 5 tracked pipeline programs.

Pipeline (5)

project

sepofarsen

Leber Congenital Amaurosis 10

Phase 3 · small_molecule · active

2 trials project

QR-010

Cystic Fibrosis

Phase 2 · small_molecule · completed

2 trials project

QR-1123

Autosomal Dominant Retinitis Pigmentosa

Phase 2 · small_molecule · active

1 trials project

QR-421a

Retinitis Pigmentosa

Phase 2 · small_molecule · completed

1 trials project

QR-504a

Fuchs Endothelial Corneal Dystrophy

Phase 1 · small_molecule · terminated

1 trials

Patents (8)

patent

US 12275937

Stereospecific linkages in RNA editing oligonucleotides

Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12203072

Chemically modified single-stranded rna-editing oligonucleotides

Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12180471

Antisense oligonucleotides for the treatment of Stargardt disease

Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12018257

Single-stranded RNA-editing oligonucleotides

Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11920132

Oligonucleotide therapy for Leber congenital amaurosis

Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11851656

Chemically modified single-stranded RNA-editing oligonucleotides

Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11649454

Single-stranded RNA-editing oligonucleotides

Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11479771

Antisense oligonucleotides for the treatment of eye disease

Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)